# Neuromuscular Disorders

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/neuromuscular-disorders/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 0960-8966 |
| ISSNs | 0960-8966,1873-2364 |
| OpenAlex ID | https://openalex.org/S50004817 |
| Publisher | Elsevier BV |

## Journal papers

Showing 12 of 19.

- [Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care](https://scholariq.org/papers/diagnosis-and-management-of-spinal-muscular-atrophy-part-1-recommendations-for/)
- [Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics](https://scholariq.org/papers/diagnosis-and-management-of-spinal-muscular-atrophy-part-2-pulmonary-and-acute/)
- [Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study](https://scholariq.org/papers/nusinersen-initiated-in-infants-during-the-presymptomatic-stage-of-spinal/)
- [224th ENMC International Workshop:](https://scholariq.org/papers/224th-enmc-international-workshop/)
- [239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018](https://scholariq.org/papers/239th-enmc-international-workshop-classification-of-dermatomyositis-amsterdam/)
- [Progressive myopathy with up-regulation of MHC-I associated with statin therapy](https://scholariq.org/papers/progressive-myopathy-with-up-regulation-of-mhc-i-associated-with-statin-therapy/)
- [Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go](https://scholariq.org/papers/newborn-screening-programs-for-spinal-muscular-atrophy-worldwide-where-we-stand/)
- [Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies1This paper was presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN, USA, April 1998.1](https://scholariq.org/papers/immunolocalization-of-tumor-necrosis-factor-alpha-and-its-receptors-in/)
- [European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene](https://scholariq.org/papers/european-medicines-agency-review-of-ataluren-for-the-treatment-of-ambulant/)
- [A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy](https://scholariq.org/papers/a-randomized-placebo-controlled-phase-3-trial-of-an-antisense-oligonucleotide/)
- [Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy](https://scholariq.org/papers/calpain-3-gene-mutations-genetic-and-clinico-pathologic-findings-in-limb-girdle/)
- [Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy](https://scholariq.org/papers/reliability-and-feasibility-of-the-six-minute-walk-test-in-subjects-with/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.